RHEUMATOID FACTOR IN GENERAL MEDICAL PRACTICE: PART II - DETECTABILITY AND CLINICAL SIGNIFICANCE IN NON-RHEUMATIC DISEASES


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

In the previous part of the publication1, the aspect of increase of rheumatoid factor in various rheumatic diseases was discussed. However, the nonspecificity of this marker, along with other things, makes it pissible to be increased in healthy people, as well as in other non-rheumatic (infectious, oncological, occupational) conditions, which is the subject of discussion in current article.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Vera LYALINA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: vera_lyalina@mail.ru
PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Elina SKRIPNICHENKO

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: elkaskrip@gmail.com
postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Rostislav BINYAKOVSKY

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: binyakovskiy@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Svetlana BORISOVSKAYA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: svabor@inbox.ru
PhD., associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Victoria DOLGOPOLOVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: dolgopolovavika@rambler.ru
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Tamara DEMURIA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: tamunademuria078@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Diana BABAYAN

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: dbabayan38@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Anna BOCHAROVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: bocharova.aan@gmail.com
clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Yulia POLYAKOVA

V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: kirichenkoyly@yandex.ru
therapist of the admission Department Moscow

Vadim GULSHIN

V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow

Email: vadimgulshin@gmail.com
therapist of the admission Department Moscow

Anna MODESTOVA

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: a.modestowa@yandex.ru
PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine Moscow

Igor NIKITIN

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia; National Medical Research Center «Treatment and Rehabilitation Center» of the Ministry of Healthcare of Russia

Email: igor.nikitin.64@mail.ru
MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Director of the National Medical Research Center «Treatment and rehabilitation center» of the Ministry of Healthcare of Russia. Moscow

Әдебиет тізімі

  1. Shmerling R.H. Rheumatoid factor: Biology and utility of measurement. 2021. URL: https://www.uptodate.com/contents/rheumatoid-factor-biology-and-utility-of-measurement (date of access - 11.02.2022).
  2. Tiwari V., Jandu J.S., Bergman M.J. Rheumatoid Factor. 2021. StatPearls Publishing. URL: https://pubmed.ncbi.nlm.nih.gov/30422493 (date of access - 11.02.2022).
  3. ngegnoli F., Castelli R., Gualtierotti R. Rheumatoid factors: Clinical applications. Dis Markers. 2013; 35(6): 727-34. https://dx.doi.org/10.1155/2013/726598.
  4. Хоббс К. Лабораторные исследования. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 64-73. ISBN: 978-5-9704-4508-2.
  5. Сидоров А.Ю. Диссертация на соискание ученой степени кандидата биологических наук «Механизм формирования эпитопов, распознаваемых регуляторным ревматоидным фактором, на FC фрагментах иммуноглобулина G человека». 2021.
  6. Newkirk M.M. Rheumatoid factors: Host resistance or autoimmunity? Clin Immunol. 2002; 104(1): 1-13. https://dx.doi.org/10.1006/clim.2002.5210.
  7. Ugolini A., Nuti M. Rheumatoid factor: A novel determiner in cancer history. Cancers (Basel). 2021; 13(4): 591. https://dx.doi.org/10.3390/cancers13040591.
  8. Isenberg D.A., Maddison P., Swana G. et al. Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections. Clin Exp Immunol. 1987; 67(3): 516-23.
  9. Kujala G.A., Steere A.C., Davis IV J.S. IgM rheumatoid factor in Lyme disease: Correlation with disease activity, total serum IgM, and IgM antibody to Borrelia burgdorfer. J Rheumatol. 1987; 14(4): 772-76.
  10. Cerny E.H., Farshy C.E., Hunter E.F., Larsen S.A. Rheumatoid factor in syphilis. J Clin Microbiol. 1985; 22(1): 89-94. https://dx.doi.org/10.1128/jcm.22.1.89-94.1985.
  11. El-Gendy H., El-Gohary R.M., Shohdy K.S., Ragab G. Leprosy masquerading as systemic rheumatic. J Clin Rheumatol. 2016; 22(5): 264-71. https://dx.doi.org/10.1097/RHU.0000000000000379.
  12. Dionello C.F., Rosa Utiyama S.R., Radominski S.C. et al. Evaluation of rheumatoid factor and anti-citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil.Int J Rheum Dis. 2016; 19(10): 1024-31. https://dx.doi.org/10.1111/1756-185X.12668.
  13. Khateeb M.I., Araj G.F., Majeed S.A., Lulu A.R. Brucella arthritis: A study of 96 cases in Kuwait. Ann Rheum Dis. 1990; 49(12): 994-98. https://dx.doi.org/10.1136/ard.49.12.994.
  14. Williams R.C. Rheumatoid factors in subacute bacterial endocarditis and other infectious diseases. Scand J Rheumatol Suppl. 1988; 75: 300-8. https://dx.doi.org/10.3109/03009748809096782.
  15. Marks M., Marks J.L. Viral arthritis. Clin Med. 2016; 2(16): 129-34. https://dx.doi.org/10.7861/clinmedicine.16-2-129.
  16. Мальцева Г.С., Уханова М.А., Тырнова Е.В. Клиническое значение определения ревматоидного фактора, С-реактивного белка, антистрептолизина-О у больных с хроническим тонзиллитом. Российская оториноларингология. 2010; 4: 45-51.
  17. Pavic S., Antic M., Sparic R., Pavic A. Clinical course of coxsackievirus B (1-6) infection. PONS - medicinski casopis. 2020; 17(1): 3-7. https://dx.doi.org/10.5937/pomc17-25015.
  18. El-Mekki A., Deverajan L. V., Soufi S. et al. Specific and non-specific serological markers in the screening for congenital CMV infection. Epidemiol Infect. 1988; 101(3): 495-501. https://dx.doi.org/10.1017/s0950268800029381.
  19. Zengin O., Yildiz H., Demir Z.H. et al. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review. Adv Clin Exp Med. 2017; 26(6): 987-90. https://dx.doi.org/10.17219/acem/63095.
  20. Lormeau C., Falgarone G., Roulot D., Boissier M.-C. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine. 2006; 73(6): 633-38. https://dx.doi.org/10.1016/j.jbspin.2006.05.005.
  21. Du Toit R., Whitelaw D., Taljaard J.J. et al. Lack of specificity of anticyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. J Rheumatol. 2011; 38(6): 1055-60. https://dx.doi.org/10.3899/jrheum.100713.
  22. Ziola B., Salmi A., Panelius M., Halonen P. Measles virus-specific IgM antibodies and IgM-class rheumatoid factor in serum and cerebrospinal fluid of subacute sclerosing panencephalitis patients. Clin Immunol Immunopathol. 1979; 13(4): 462-74. https://dx.doi.org/10.1016/0090-1229(79)90089-8.
  23. Kerr J.R., Cunniffe V.S., Kelleher P. et al. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol. 2004; 74(1): 147-55. https://dx.doi.org/10.1002/jmv.20158.
  24. Harboe M. Rheumatoid factors in leprosy and parasitic diseases. Scand J Rheumatol Suppl. 1988; 75: 309-13. https://dx.doi.org/10.3109/03009748809096783.
  25. Houba V., Allison A.C. M-antiglobulins (rheumatoid-factor-like globulins) and other gammaglobulins in relation to tropical parasitic infections. Lancet. 1966; 1(7442): 848-52. https://dx.doi.org/10.1016/s0140-6736(66)90186-3.
  26. Utiyama S.R.R., Zenatti K.B., Nobrega H.A.J. et al. Rheumatic disease autoantibodies in autoimmune liver diseases. Immunol Invest. 2016; 45(6): 566-73. https://dx.doi.org/10.1080/08820139.2016.1186173.
  27. Palazzi C., Buskila D., D'Angelo S. et al. Autoantibodies in patients with chronic hepatitis C virus infection: Pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev. 2012; 11(9): 659-63. https://dx.doi.org/10.1016/j.autrev.2011.11.011.
  28. Энн Койл К. Вирусные артриты. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; 335-341. ISBN: 978-5-9704-4508-2.
  29. Cunha B.M., Mota L.M.H., Pileggi G.S. et al. HIV/AIDS and rheumatoid arthritis. Autoimmun Rev. 2015; 14(5): 396-400. https://dx.doi.org/10.1016/j.autrev.2015.01.001.
  30. ФБУН «Центральный НИИ эпидемиологии Роспотребнадзора», Федеральный научно-методический центр по профилактике и борьбе со СПИДом. Последние эпидемиологические данные по ВИЧ-инфекции в Российской Федерации (по состоянию на 30.06.2021 г.). 2021. Доступ: http://www.hivrussia.info (дата обращения - 01.07.2021). URL: http://www.hivrussia.info (date of access - 01.07.2021) (In Russ.)].
  31. Кубанова А.А., Кубанов А.А., Мелехина Л.Е. Заболеваемость сифилисом в Российской Федерации за период 2006-2016 гг. Вестник дерматологии и венерологии. 2017; 5: 16-25. https://dx.doi.org/10.25208/0042-4609-2017-93-5-16-25.
  32. Watanabe K., Ohkubo Y., Funahashi Y. et al. An investigation on rheumatoid factor of different immunoglobulin classes in hepatitis B virus carriers. Clin Rheumatol. 1991; 10(1): 31-7. https://dx.doi.org/10.1007/BF02208030.
  33. Всемирная организация здравоохранения. Лепра. 2021. Доступ: https://www.who.int/ru/news-room/fact-sheets/detail/leprosy (дата обращения - 11.02.2022).
  34. National Hansen's Disease (Leprosy) Program Caring and Curing since 1894. Hansen's disease (leprosy) facts. 2021. URL: https://www.hrsa.gov/hansens-disease/index.html (date of access - 11.02.2022).
  35. Дуйко В.В. К международному дню больного лепрой. 2021. Доступ: https://www.inlep.ru/post/к-международному-дню-больного-лепрой (дата обращения - 11.02.2022).
  36. Salvi S., Chopra A. Leprosy in a rheumatology setting: A challenging mimic to expose. Clin Rheumatol. 2013; 32(10): 1557-63. https://dx.doi.org/10.1007/s10067-013-2276-5.
  37. Головизнин М.В., Булдакова Ю.Р., Тимофеев В.Т., Лахонина Н.С. Лепра и ревматоидный артрит с узелками. «Две стороны медали» системного гранулематозного воспаления. РМЖ. Медицинское обозрение. 2017; 1: 16-21.
  38. Охапкина, В.Ю., Пяткова Н.В., Павлов Д.Л., Суслопаров А.А. Эпидемическая опасность бруцеллеза в современных условиях. Эпидемиология и вакцинопрофилактика. 2016; 3: 15-22.
  39. Dean A.S., Crump L., Greter H. et al. Clinical manifestations of human brucellosis: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2012; 6(12): e1929. https://dx.doi.org/10.1371/journal.pntd.0001929.
  40. Нечаева О.Б. Эпидемическая ситуация по туберкулезу в России. Туберкулез и болезни легких. 2018; 8: 15-24. https://dx.doi.org/10.21292/2075-1230-2018-96-8-15-24.
  41. Elkayam O., Segal R., Lidgi M., Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006; 65(8): 1110-12. https://dx.doi.org/10.1136/ard.2005.045229.
  42. Lima I., Oliveira R.C., Atta A. et al. Antibodies to citrullinated peptides in tuberculosis. Clin Rheumatol. 2013; 32(5): 685-87. https://dx.doi.org/10.1007/s10067-013-2173-y.
  43. Токмалаев А.К., Баранова А.М., Малеев В.В. Эпидемиологические и клинические аспекты диагностики, лечения и профилактики завозных случаев малярии в Российской Федерации. Терапевтический архив. 2020; 11: 77-81. https://dx.doi.org/10.26442/00403660.2020.11.000812.
  44. Yaffe I. Scanty congenital plasmodium parasites as a possible cause for several autoimmune diseases. Med Hypotheses. 2001; 56(3): 335-38. https://dx.doi.org/10.1054/mehy.2000.1151.
  45. Green T.J., Packer B.J. A role for rheumatoid factor enhancement of Plasmodium falciparum schizont inhibition in vitro. Infect Immun. 1984; 46(3): 668-72. https://dx.doi.org/10.1128/iai.46.3.668-672.1984.
  46. Alvarez-Hernandez D.-A., Franyuti-Kelly G.-A., Diaz-Lopez-Silva R. et al. Chagas disease: Current perspectives on a forgotten disease. Revista Médica del Hospital General de Mexico. 2018; 81(3): 154-64. https://dx.doi.org/10.1016/j.hgmx.2016.09.010.
  47. Nguyen T., Waseem M. Chagas Disease. 2021. StatPearls Publishing. URL: https://pubmed.ncbi.nlm.nih.gov/29083573 (date of access - 11.02.2022).
  48. Gradoni L., Lopez-Velez R., Mokni M. Руководство по ведению случаев и эпиднадзору за лейшманиозами в европейском регионе ВОЗ. 2018. Доступ: https://www.euro.who.int/data/assets/pdf_file/0004/372820/leishmaniasis-rus.pdf (дата обращения - 11.02.2022).
  49. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Письмо «О ситуации по лейшманиозам в Российской Федерации». 2015. Доступ: https://docs.cntd.ru/document/420268897 (дата обращения - 11.02.2022).
  50. World Health Organization. Onchocerciasis. URL: https://www.who.int/ru/news-room/fact-sheets/detail/onchocerciasis (date of access - 11.02.2022).
  51. Токмалаев А.К. Гельминтозы человека. РМЖ. 2001; 16: 690.
  52. James S.L., Abate D., Abate K.H. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1789-858. https://dx.doi.org/10.1016/S0140-6736(18)32279-7.
  53. Salemi S., D'Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol. 2010; 29(3): 247-69. https://dx.doi.org/10.3109/08830181003746304.
  54. Welch M.J., Fong S., Vaughan J., Carson D. Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol. 1983; 51(2): 299-304.
  55. Tarkowski A., Czerkinsky C., Nilsson L.A. Simultaneous induction of rheumatoid factor- and antigen-specific antibody-secreting cells during the secondary immune response in man. Clin Exp Immunol. 1985; 61(2): 379-87.
  56. Procaccia S., Borroni G., Lanzanova D. et al. IgG rheumatoid factors behaviour in young normal subjects following vaccination. Boll Ist Sieroter Milan. 1983; 62(5): 451-61.
  57. Матвеичев А.В., Мохонова Е.В., Никитина З.И. с соавт. Опыт оценки аутоиммунного гомеостаза при вакцинации - вакцина «Пневмо 23». Вестник Санкт-Петербургского университета. Медицина. 2013; 4: 76-87.
  58. Матвеичев А.В., Талаева М.В., Талаев В.Ю. с соавт. Оценка аутоиммунного гомеостаза у лиц, вакцинированных против бак териальных и вирусных респираторных инфекций. Иммунология. 2016; 5: 256-261.https://dx.doi.org/10.18821/0206-4952-2016-37-5-256-261.
  59. Gualtierotti R., Ciavarella T., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 3rd edition. Ed. by Shoenfeld Y., Meroni P.L., Gershwin V.E. Amsterdam: Elsevier B.V. 2014; 751-60. ISBN: 978-0-444-56378-1. https://dx.doi.org/10.1016/C2010-0-68545-2.
  60. Раденска-Лоповок С.Г., Волкова П. Аутоиммунный/ воспалительный синдром, ассоциированный с адъювантами. Архив патологии. 2018; 5: 56-62. https://dx.doi.org/10.17116/patol20188005156.
  61. Colaris M.J.L., de Boer M., van der Hulst R.R., Cohen Tervaert J.W. Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. Immunol Res. 2017; 65(1): 120-28. https://dx.doi.org/10.1007/s12026-016-8821-y.
  62. Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 5: 66-73 https://dx.doi.org/10.20969/VSKM.2017.10(5).66-73.
  63. Oreskes I., Siltzbach L.E. Changes in rheumatoid factor activity during the course of sarcoidosis. Am J Med. 1968; 44(1): 60-67. https://dx.doi.org/10.1016/0002-9343(68)90237-4.
  64. Kobak S., Yilmaz H., Sever F. et al. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. 2014; 2014: 351852. https://dx.doi.org/10.1155/2014/351852.
  65. Российское респираторное общество. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. 2016. Доступ: https://spulmo.ru/download/IPFrec.pdf (дата обращения - 11.02.2022).
  66. Kamiya H., Panlaqui O.M. Systematic review and meta-Analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis. BMJ Open. 2019; 9(5): e027849. https://dx.doi.org/10.1136/bmjopen-2018-027849.
  67. Kang B.H., Park J.K., Roh J.H. et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci. 2013; 28(5): 731-37. https://dx.doi.org/10.3346/jkms.2013.28.5.731.
  68. Пенкина Т.В., Шикина Е.А., Дичева Д.Т. с соавт. Первичный билиарный холангит - новая нозологическая единица в классификации болезней печени (обзор литературы и собственное клиническое наблюдение). Медицинский совет. 2019; 3: 76-82. https://dx.doi.org/10.21518/2079-701X-2019-3-76-82.
  69. Culp K.S., Fleming C.R., Duffy J. et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc. 1982; 57(6): 365-70.
  70. Bartfeld H. Distribution of rheumatoid factor activity in nonrheumatoid states. Ann N Y Acad Sci. 1969; 168(1): 30-40. https://dx.doi.org/10.1111/j.1749-6632.1969.tb43092.x.
  71. Gupta N.P., Malaviya A.N., Singh S.M. Rheumatoid factor: Correlation with recurrence in transitional cell carcinoma of the bladder. J Urol. 1979; 121(4): 417-18. https://dx.doi.org/10.1016/s0022-5347(17)56803-2.
  72. Schattner A., Shani A., Talpaz M., Bentwich Z. Rheumatoid factors in the sera of patients with gastrointestinal carcinoma. Cancer. 1983; 52(11): 2156-61. https://dx.doi.org/10.1002/1097-0142(19831201)52:11<2156::aid-cncr2820521130>3.0.co;2-2.
  73. Ugolini A., Zizzari I.G., Ceccarelli F. et al. IgM-rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. EBioMedicine. 2020; 62: 103098. https://dx.doi.org/10.1016/j.ebiom.2020.103098.
  74. Sherlock S., Scheuer P.J. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med. 1973; 289(13): 674-78. https://dx.doi.org/10.1056/NEJM197309272891306.
  75. Shmerling R.H., Delbanco T.L. The rheumatoid factor: An analysis of clinical utility. Am J Med. 1991; 91(5): 528-34. https://dx.doi.org/10.1016/0002-9343(91 )90190-9.
  76. Mimura Y., Ihn H., Jinnin M. et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol. 2005; 30(4): 405-8. https://dx.doi.org/10.1111/j.1365-2230.2005.01776.x.
  77. Boyd J.E., Robertson M.D., Davis J.M.G. Autoantibodies in coalminers: Their relationship to the development of progressive massive fibrosis. Am J Ind Med. 1982; 3(2): 201-8. https://dx.doi.org/10.1002/ajim.4700030211.
  78. Doll N.J., Stankus R.P., Hughes J. et al. Immune complexes and autoantibodies in silicosis. J Allergy Clin Immunol. 1981; 68(4): 281-85. https://dx.doi.org/10.1016/0091-6749(81)90152-4.
  79. Lange A. An epidemiological survey of immunological abnormalities in asbestos workers. II. Serum immunoglobulin levels. Environ Res. 1980; 22(1): 176-83. https://dx.doi.org/10.1016/0013-9351(80)90129-2.
  80. Morris D.L., Greenberg S.D., Lawrence E.C. Immune responses in asbestos-exposed individuals. Chest. 1985; 87(3): 278-80. https://dx.doi.org/10.1378/chest.87.3.278.
  81. Warwick M.T., Haslam P., Weeks J. Antibodies in some chronic fibrosing lung diseases: II. Immunofluorescent studies. Clin Allergy. 1971; 1(2): 209-19. https://dx.doi.org/10.1111/j.1365-2222.1971.tb03020.x.
  82. Leung C.C., Yu I.T.S., Chen W. Silicosis. Lancet. 2012; 379(9830): 2008-18. https://dx.doi.org/10.1016/S0140-6736(12)60235-9.
  83. Barber C.M., Fishwick D., Carder M., Van Tongeren M. Epidemiology of silicosis: Reports from the SWORD scheme in the UK from 1996 to 2017. Occup Environ Med. 2019; 76(1): 17-21. https://dx.doi.org/10.1136/oemed-2018-105337.
  84. Zaghi G., Koga F., Nisihara R.M. et al. Autoantibodies in silicosis patients and in silica-exposed individuals. Rheumatol Int. 2010; 30(8): 1071-75. https://dx.doi.org/10.1007/s00296-009-1116-z.
  85. Accurate results in the clinical laboratory: A guide to error detection and correction. 2nd Edition. Ed. by Dasgupta A., Sepulveda J. Amsterdam: Elsevier B.V. 2019; pp. 75-81. ISBN: 978-0-128-13777-2.
  86. Lavoie S., Caswell D., Gill M.J. et al. Heterophilic interference in specimens yielding false-reactive results on the Abbott 4th generation ARCHITECT HIV Ag/Ab Combo assay. J Clin Virol. 2018; 104: 23-28. https://dx.doi.org/10.1016/j.jcv.2018.03.014.
  87. Li Y., Yang F., Ji X. et al. False human immunodeficiency virus test results associated with rheumatoid factors in rheumatoid arthritis. Chin Med Sci J. 2014; 29(2): 103-6. https://dx.doi.org/10.1016/s1001-9294(14)60036-5.
  88. Kharlamova N., Dunn N., Bedri S.K. et al. False positive results in SARS-CoV-2 serological tests for samples from patients with chronic inflammatory diseases. Front Immunol. 2021; 12: 666114. https://dx.doi.org/10.3389/fimmu.2021.666114.
  89. Wang H., Bi X., Xu L., Li Y. Negative interference by rheumatoid factor in alpha-fetoprotein chemiluminescent microparticle immunoassay. Ann Clin Biochem. 2017; 54(1): 55-59. https://dx.doi.org/10.1177/0004563216636646.
  90. Мошкин А.В. Обнаружение интерференции как составляющая валидации результата лабораторного исследования. Лабораторная служба. 2018; 4: 3-4. https://dx.doi.org/10.17116/labs201870413.
  91. Olsson P., Theander E., Bergstrom U. et al. Multiplex cytokine analyses in patients with rheumatoid arthritis require use of agents blocking heterophilic antibody activity. Scand J Rheumatol. 2017; 46(1): 1-10. https://dx.doi.org/10.3109/03009742.2016.1161070.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>